Proceedings of the 2018 International Workshop on Bioinformatics, Biochemistry, Biomedical Sciences (BBBS 2018)

Effects of Rifapentine and Rifampicin in Smear-positive Pulmonary Tuberculosis Patients and the Incidence Comparison of Complications

Authors
Jianmei Ma, Hongyang Shi, Yan Zhang
Corresponding Author
Jianmei Ma
Available Online April 2018.
DOI
https://doi.org/10.2991/bbbs-18.2018.20How to use a DOI?
Keywords
Smear-positive tuberculosis; rifapentine; rifampin; clinical effect; complications
Abstract

Objective: to analyze the clinical effects and complications of rifapentine and rifampicin in patients with smear-positive pulmonary tuberculosis. Methods: from August 2013 to June 2017, 100 of the smear-positive pulmonary tuberculosis patients treated in our hospital were selected and divided into two groups according to treatment methods. Patients in the control group were treated with rifampicin + isoniazid + pyrazinamide + ethambutol, while patients in the observation group were treated with rifapentine + isoniazid + pyrazinamide + ethambutol. In addition to the nisus absorption rate, the cavity closure rate and the rate of sputum negative conversion after the treatment, the comparison was also applied on the level of peripheral blood T-lymphocyte subsets and the incidence of complications before and after the treatment. Results: compared with the control group, patients in the observation group had higher levels of CD8+, CD4+ and CD3+ in peripheral blood T lymphocyte subsets; the nisus absorption rate, cavity closure rate and the rate of sputum negative conversion in the observation group were higher after treatment, and the difference between the groups was statistically significant (P<0.05); the incidence of complications in the observation group was 6%, which was lower than that in the control group (22%). There was a statistically significant difference between the two groups (P<0.05). Conclusion: the clinical efficacy of rifapentine in smear-positive pulmonary tuberculosis patients is superior to that of rifampicin and therefore it worth being promoted

Copyright
© 2018, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

Volume Title
Proceedings of the 2018 International Workshop on Bioinformatics, Biochemistry, Biomedical Sciences (BBBS 2018)
Series
Advances in Biological Sciences Research
Publication Date
April 2018
ISBN
978-94-6252-511-5
ISSN
2468-5747
DOI
https://doi.org/10.2991/bbbs-18.2018.20How to use a DOI?
Copyright
© 2018, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - CONF
AU  - Jianmei Ma
AU  - Hongyang Shi
AU  - Yan Zhang
PY  - 2018/04
DA  - 2018/04
TI  - Effects of Rifapentine and Rifampicin in Smear-positive Pulmonary Tuberculosis Patients and the Incidence Comparison of Complications
BT  - Proceedings of the 2018 International Workshop on Bioinformatics, Biochemistry, Biomedical Sciences (BBBS 2018)
PB  - Atlantis Press
SP  - 87
EP  - 91
SN  - 2468-5747
UR  - https://doi.org/10.2991/bbbs-18.2018.20
DO  - https://doi.org/10.2991/bbbs-18.2018.20
ID  - Ma2018/04
ER  -